title: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.
abstract: BACKGROUND
  We have previously reported a virtual absence of neointimal hyperplasia 4 months after implantation of sirolimus-eluting stents. The aim of the present investigation was to determine whether these results are sustained over a period of 1 year.
  
  
  RESULTS
  Forty-five patients with de novo coronary disease were successfully treated with the implantation of a single sirolimus-eluting Bx VELOCITY stent in São Paulo, Brazil (n=30, 15 fast release [group I, GI] and 15 slow release [GII]) and Rotterdam, The Netherlands (15 slow release, GIII). Angiographic and volumetric intravascular ultrasound (IVUS) follow-up was obtained at 4 and 12 months (GI and GII) and 6 months (GIII). In-stent minimal lumen diameter and percent diameter stenosis remained essentially unchanged in all groups (at 12 months, GI and GII; at 6 months, GIII). Follow-up in-lesion minimal lumen diameter was 2.28 mm (GIII), 2.32 mm (GI), and 2.48 mm (GII). No patient approached the >/=50% diameter stenosis at 1 year by angiography or IVUS assessment, and no edge restenosis was observed. Neointimal hyperplasia, as detected by IVUS, was virtually absent at 6 months (2+/-5% obstruction volume, GIII) and at 12 months (GI=2+/-5% and GII=2+/-3%).
  
  
  CONCLUSIONS
  This study demonstrates a sustained suppression of neointimal proliferation by sirolimus-eluting Bx VELOCITY stents 1 year after implantation.
authors.affiliation: Institute Dante Pazzanese of Cardiology, São Paulo, Brazil. jesousa@uol.com.br
authors.forename: J E
authors.initials: JE
authors.lastname: Sousa
authors.forename: M A
authors.initials: MA
authors.lastname: Costa
authors.forename: A C
authors.initials: AC
authors.lastname: Abizaid
authors.forename: B J
authors.initials: BJ
authors.lastname: Rensing
authors.forename: A S
authors.initials: AS
authors.lastname: Abizaid
authors.forename: L F
authors.initials: LF
authors.lastname: Tanajura
authors.forename: K
authors.initials: K
authors.lastname: Kozuma
authors.forename: G
authors.initials: G
authors.lastname: Van Langenhove
authors.forename: A G
authors.initials: AG
authors.lastname: Sousa
authors.forename: R
authors.initials: R
authors.lastname: Falotico
authors.forename: J
authors.initials: J
authors.lastname: Jaeger
authors.forename: J J
authors.initials: JJ
authors.lastname: Popma
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D001938:Brazil; D015331:Cohort Studies; D017023:Coronary Angiography; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004343:Drug Implants / Q000008:administration & dosage; D019160:Endosonography; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D015607:Stents / Q000009:adverse effects; D015996:Survival Rate; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D003692:Delayed-Action Preparations; D004343:Drug Implants; D020123:Sirolimus